IFNB1 and COVID-19: The addition of IFNβ to COVID-19 antiviral regimen might block IL-19 stimulated cytokines by downregulating IL-19 and attenuating STAT3 signaling, leading to better control of cytokine storm and the associated COVID-19 hyperinflammation condition.